University of Minnesota

University of Miami

S Mbua Efange

Deborah Carmen Mash

Stanley M Parsons

Compounds of formula I: ##STR1## wherein R.sup.1, R.sup.2, W, X, Y and Z have any of the values defined in the specification, and their pharmaceutically acceptable salts, are inhibitors of monoamine re-uptake and are useful for treating diseases in mammals wherein insufficient synaptic levels of monoamine are implicated. Also disclosed are pharmaceutical compositions, processes for preparing compounds of formula I, and intermediates useful for the synthesis of compounds of formula I.

Spiroindanamines and Spiroindanimides

Compounds of formula I or formula II: ##STR1## wherein R, J, and Q have any of the values defined in the specification, and their pharmaceutically acceptable salts and related radiopharmaceuticals, have anticholinergic activity, and are useful for modulating cholinergic function in mammals. Also disclosed are pharmaceutical compositions, processes for preparing compounds of formula (I) or (II) and intermediates.

Decahydroquinoline-based anti-cholinergic agents

Ibogaine analogs are provided, which are phenyl-substituted-hexahydroazepino[4,5-b]indoles useful to treat cocaine addiction and the use of other addictive substances.

Growing community of inventors

Plymouth, MN, United States of America

S Mbua Efange